Epizyme (EPZM) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
February 23, 2021 6:30 AM ESTTotal Revenue of $8.4 Million for 4Q 2020; $15.8 Million for FY 2020
TAZVERIK® Net Revenues of $4.5 Million for 4Q 2020; $11.5 Million for FY 2020
Safety Run-In Portion of Confirmatory Trials of TAZVERIK® in ES and FL and Phase 2 Castration-Resistant Prostate Cancer Fully Enrolled; Initial Safety & Activity Data Expected in 2021
Strong Balance Sheet with Approximately $374 Million in Cash and Marketable Securities at Year-End 2020
Conference Call Today, February 23 at 8:00 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS... More
